A COMPREHENSIVE REVIEW OF ADVERSE EFFECTS OF BIOLOGICAL TREATMENT IN ASTHMA
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6194Keywords:
Severe asthma, Biologic therapy, Adverse effects, Safety profileAbstract
Background: Biologic therapies have revolutionized the treatment of severe asthma by targeting specific inflammatory pathways, reducing exacerbation rates, improving lung function, and decreasing dependence on systemic corticosteroids. Despite their proven efficacy, concerns regarding adverse effects may limit their acceptance and early implementation in clinical practice.
Objective: This review aimed to evaluate and summarize the adverse effects associated with currently approved biologic agents for asthma treatment, including omalizumab, benralizumab, mepolizumab, dupilumab, and tezepelumab.
Methods: A narrative literature review was conducted using the PubMed database. English-language studies published between January 2011 and May 2026 were analyzed, including randomized controlled trials, systematic reviews, meta-analyses, observational studies, and selected case reports. Particular attention was paid to the incidence and clinical significance of hypersensitivity reactions, infections, eosinophilia, cardiovascular events, and malignancies.
Results: The reviewed biologics demonstrated favorable safety profiles, with most adverse events being mild to moderate and rarely leading to treatment discontinuation. Omalizumab was associated with a rare risk of anaphylaxis, while dupilumab was linked to transient eosinophilia and uncommon eosinophilic complications. Benralizumab, mepolizumab, and tezepelumab showed reassuring long-term safety data, with no significant increase in severe infections, malignancies, or cardiovascular events. Across all agents, the incidence of serious adverse reactions remained low.
Conclusions: Current evidence indicates that the clinical benefits of biologic therapies in severe asthma substantially outweigh their potential risks. Improved awareness of their safety profiles may reduce patient concerns and facilitate earlier treatment initiation, reduce corticosteroid-related complications, and contribute to better long-term outcomes and quality of life in patients with severe asthma.
References
Linda Cox, Phillip Lieberman, Dana Wallace, F.Estelle R. Simons et al., American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report, The Yournal of Allergy and Clinical Immunology, Volume 128, Issue 1, P 210-212, July 2011, https://doi.org/10.1016/j.jaci.2011.04.010
Lieberman PL, Jones I, Rajwanshi R, et al. Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics. J Allergy Clin Immunol 2017; 140(6): 1734–1736.e4., https://doi.org/10.1016/j.jaci.2017.07.013
Harrison RG, MacRae M, Karsh J, Santucci S, Yang WH. Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience. Ann Allergy Asthma Immunol. 2015 Jul;115(1):77-8. https://doi.org/10.1016/j.anai.2015.04.014
Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol. 2007 Oct;120(4):972-3. https://doi.org/10.1016/j.jaci.2007.06.038
Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, et al., Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007 Feb;37(2):197-207. https://doi.org/10.1111/j.1365-2222.2007.02650.x
Puéchal X, Rivereau P, Vinchon F, Churg–Strauss syndrome associated with omalizumab, European Journal of Internal Medicine, Volume 19, Issue 5, P364-366, July 2008, https://doi.org/10.1016/j.ejim.2007.09.001
Long, A. ∙ Rahmaoui, A. et al, Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab, J Allergy Clin Immunol. 2014; 134:560-567.e4
Pongdee T, Li J, Omalizumab safety concerns, Journal of Allergy and Clinical Immunology, Volume 155, Issue 1P31-35January 2025, https://doi.org/10.1016/j.jaci.2024.11.005
Iribarren C, Rothman KJ, Bradley MS, Carrigan G, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017 May;139(5):1678-1680. https://doi.org/10.1016/j.jaci.2016.12.953
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18;380(9842):651-9. https://doi.org/10.1016/S0140-6736(12)60988-X
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1198-207. https://doi.org/10.1056/NEJMoa1403290
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189-97. https://doi.org/10.1056/NEJMoa1403291
Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017 May;5(5):390-400. https://doi.org/10.1016/S2213-2600(17)30125-X
Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clin Ther. 2016 Sep;38(9):2058-2070.e1. https://doi.org/10.1016/j.clinthera.2016.07.010
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, et al., Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019 May;143(5):1742-1751.e7. https://doi.org/10.1016/j.jaci.2018.09.033
Busse W, Bleecker E, FitzGerald J et al, Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial, The Lancet Respiratory Medicine, 2018; 7, 46-59, https://doi.org/10.1016/S2213-2600(18)30406-5
Jackson DJ, Korn S, Mathur SK, Barker P, Meka VG, et al. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab. Drug Saf. 2020 May;43(5):409-425. https://doi.org/10.1007/s40264-020-00926-3
Van Vaerenbergh F, Vauterin D, Grymonprez M, Vanfleteren LEGW, et al. Cardiovascular safety of biologic therapies in patients with severe asthma: a nationwide cohort study in Belgium. Lancet Reg Health Eur. 2025 Aug 6;57:101420. https://doi.org/10.1016/j.lanepe.2025.101420
Ameer OZ, Mansour GK, Al-Amoudi RS, Abu‐Owaimer FM, Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness. Front. Pharmacol. 16:1631321. https://doi.org/10.3389/fphar.2025.1631321
– Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, et al., Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-2496. https://doi.org/10.1056/NEJMoa1804092
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, et al., Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11-25. https://doi.org/10.1016/S2213-2600(21)00322-2
Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, et al., Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019 Jan;80(1):158-167.e1. https://doi.org/10.1016/j.jaad.2018.07.048
Olaguibel JM, Sastre J, Rodríguez JM, Del Pozo V. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes. J Investig Allergol Clin Immunol. 2022 Jun 20;32(3):165-180. https://doi.org/10.18176/jiaci.0823
Ma KS, Brumbaugh B, Saff RR, Phipatanakul W, Tsai SY, Westmeijer M, Holt A, Ebriani J, Camargo CA Jr, Chen ST. Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study. Eur Respir J. 2025 Sep 25;66(3):2500139. https://doi.org/10.1183/13993003.00139-2025
Lugogo NL, Akuthota P, Sumino K, Mathur SK, Burnette AF, et al., Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study. Adv Ther. 2025 Jul;42(7):3334-3353. https://doi.org/10.1007/s12325-025-03231-6
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al., Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021 May 13;384(19):1800-1809. https://doi.org/10.1056/NEJMoa2034975
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Joanna Kadłuczka, Aleksandra Pawłucka, Katarzyna Kraska, Makary Hejduk, Jan Potoniec, Katarzyna Pawłucka, Justyna Bury, Weronika Kępa, Aneta Sobek, Martyna Więcławek, Magdalena Grzymek
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
